Vinod Ganju
A5018587056- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Prostate Cancer Treatment and Research
- Cancer Cells and Metastasis
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- Nanoparticle-Based Drug Delivery
- PARP inhibition in cancer therapy
- Medical Imaging Techniques and Applications
- Lung Cancer Diagnosis and Treatment
Peninsula Health
2015-2025
Monash University
2013-2024
Hudson Institute of Medical Research
2015-2024
Peter MacCallum Cancer Centre
1997-2024
The University of Melbourne
2024
Frankston Hospital
2007-2023
Cancer Australia
2015-2022
QIMR Berghofer Medical Research Institute
2020
Spanish National Cancer Research Centre
2018
Centre for Biomedical Network Research on Rare Diseases
2018
This phase III study compared the safety and efficacy of following three different irinotecan-containing regimens in first-line treatment metastatic colorectal cancer: irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), bolus FU/LV (mIFL), oral capecitabine (CapeIRI).A total 430 previously untreated cancer patients were randomly assigned to receive FOLFIRI (n = 144), mIFL 141), or CapeIRI 145). Patients concurrently a double-blind with celecoxib placebo. After protocol...
Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases. Patients and Methods In this multicenter, double-blind, phase III trial, were randomly assigned (2:1) 10 mg/kg placebo every 3 weeks for up four doses. maintenance therapy was administered nonprogressing...
To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients metastatic colorectal cancer (mCRC) an open-label, three-arm randomized trial.Overall, 471 Australia, New Zealand, and the United Kingdom previously untreated, unresectable mCRC were randomly assigned following: capecitabine; plus bevacizumab (CB); capecitabine, mitomycin (CBM). We compared CB CBM for (PFS). Secondary end points included overall...
Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit patients with liver metastases liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy SIRT using yttrium-90 resin microspheres metastases. were designed combined analysis overall survival.
SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres standard fluorouracil, leucovorin, oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer.Chemotherapy-naïve liver metastases plus or minus limited extrahepatic were randomly assigned receive either modified FOLFOX (mFOLFOX6; control) mFOLFOX6 SIRT bevacizumab. The...
Background Availability of checkpoint inhibitors has created a paradigm shift in the management patients with solid tumors. Despite this, most do not respond to immunotherapy, and there is considerable interest developing combination therapies improve response rates outcomes. B7-H3 (CD276) member B7 family cell surface molecules provides an alternative immune molecule therapeutically target alone or programmed death-1 (PD-1)–targeted therapies. Enoblituzumab, investigational anti-B7-H3...
PURPOSE For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) docetaxel improved OS versus ADT and in mHSPC. The ARANOTE trial evaluated darolutamide without chemotherapy METHODS In this global phase III trial, were randomly assigned 2:1 receive 600 mg twice daily or placebo, concomitant...
Abstract Background. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients metastatic pancreatic cancer (MPC), based on superiority over demonstrated the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and presence of liver metastases were shown to be predictive survival nab-paclitaxel plus treatment. This analysis sought further explore relationship between clinical characteristics trial identify potential predictors...
PURPOSE SHR-A1811 is an antibody-drug conjugate composed of anti–human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, pharmacokinetics in heavily pretreated HER2-expressing or mutated advanced solid tumors. METHODS This global, multi-center, first-in-human, phase trial was conducted at 33 centers. Patients who had unresectable, advanced, metastatic tumors were...
Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in patients oesophagogastric cancer, but high rates of haematological toxicity. Weekly docetaxel is associated less This randomised phase II study tested weekly docetaxel-based combination chemotherapy regimens, the aim maintaining their activity while reducing Patients histologically confirmed metastatic oesophageal or gastric carcinoma were receive (30 mg m−2) on days 1 8,...
Abstract Introduction. Colorectal cancer (CRC) and its treatments can cause distressing sequelae. We conducted a multicenter randomized controlled trial aiming to improve psychological distress, supportive care needs (SCNs), quality of life (QOL) patients with CRC. The intervention, called SurvivorCare (SC), comprised educational materials, assessment, survivorship plan, end-of-treatment session, three follow-up telephone calls. Methods. At the end treatment for stage I–III CRC, eligible...
Small cell lung cancer (SCLC) is an aggressive neuroendocrine with appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line platinum-based doublet chemotherapy, but almost universally relapse drug resistant disease. Elevated MYC expression common in SCLC and has been associated platinum resistance. This study evaluates the capacity drive resistance through screening identifies a capable reducing overcoming following...
Mobocertinib is a kinase inhibitor designed to selectively target epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer. This drug-drug interaction study assessed the effect of multiple-dose administration mobocertinib on pharmacokinetics (PK) midazolam, sensitive cytochrome P450 3A substrate. Patients with locally advanced or metastatic cancer refractory/intolerant standard available therapy were enrolled. In Cycle 1 (Part A; PK cycle),...
<p>Supplementary. Fig. 6. In vivo anti-tumor activity of EMB-09 parental mAbs in transgenic C57B/6 mice. a The efficacy tested antibodies alone or combination was evaluated hOX40 MC38 tumor bearing mice were treated with the indicated 7 days after implantation. 5 mg/kg 3 times at 3-days’ interval (n = 8 per group, error bar: SEM). b hPD-L1 Mice subcutaneously inoculated MC38-hPD-L1 cells. implantation, randomly allocated to different groups and (10 mg/kg) for four interval. Tumor...
<p>Supplementary. Table 3. The binding affinity of EMB-09 to Fcγ receptors was determined by BLI using Octect system.</p>